Phaserx Inc Cmn (PZRX) 2.50 $PZRX PhaseRx to Pr
Post# of 273254
PhaseRx to Present at the 2016 Aegis Growth Conference
PR Newswire - Wed Sep 14, 7:30AM CDT
PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA products to correct life-threatening inherited liver diseases in children, today announced that the company will be presenting at the 2016 Aegis Growth Conference. Robert W. Overell, Ph.D., president and chief executive officer, will provide an overview of the company and its development stage programs on Wednesday, September 21, 2016 at 3:30 p.m. PDT (6:30 p.m. EDT). The investor conference will be held from September 21-22, 2016 at the Encore at Wynn in Las Vegas.
PZRX: 2.50 (-0.09)
PhaseRx Appoints Peggy Phillips to Board of Directors
PR Newswire - Mon Aug 22, 3:05PM CDT
PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA products to correct life-threatening inherited liver diseases in children, today announced the appointment of Peggy Phillips to the company's board of directors. Ms. Phillips will be replacing Richard Ulevitch, Ph.D., of 5AM Ventures, who is resigning from the board.
PZRX: 2.50 (-0.09)
PhaseRx Reports Second Quarter 2016 Financial Results and Provides Corporate Update
PR Newswire - Tue Aug 02, 3:05PM CDT
PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing treatments for life-threatening inherited liver diseases in children, today reported financial results for the quarter and six months ended June 30, 2016 and provided an update on its corporate activities.
PZRX: 2.50 (-0.09)
PhaseRx Advances Product Pipeline for Treatment of Rare Genetic Liver Diseases
PR Newswire - Tue Jun 21, 7:00AM CDT
PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing treatments for life-threatening inherited liver diseases in children, today announced product pipeline advancements including the selection of its lead product candidate, PRX-OTC, for treatment of Ornithine Transcarbamylase Deficiency (OTCD) and positive proof-of-concept data for a second product candidate, PRX-ASL, for treatment of Argininosuccinate Lyase Deficiency (ASLD).
PZRX: 2.50 (-0.09)
PhaseRx to Present at the 2016 JMP Securities Life Sciences Conference
PR Newswire - Wed Jun 15, 7:00AM CDT
PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing treatments for life-threatening inherited liver diseases in children, today announced that the company will be presenting at the 2016 JMP Securities Life Sciences Conference. Robert W. Overell, Ph.D., President and Chief Executive Officer, will provide an overview of the company and its development stage programs on Wednesday, June 22, 2016 at 9:30 a.m. EDT (6:30 a.m. PDT). The investor conference will be held from June 21-22, 2016 in New York.
PZRX: 2.50 (-0.09)
PhaseRx Announces Closing of Initial Public Offering
PR Newswire - Mon May 23, 3:00PM CDT
PhaseRx, Inc. (NASDAQZRX), a biotechnology company focused on developing mRNA therapeutics to treat orphan liver diseases, today announced the closing of its initial public offering of 3,700,000 shares of common stock at a public offering price of $5.00 per share, resulting in aggregate gross proceeds of $18.5 million, before underwriting discounts and commissions and offering related expenses. In addition, PhaseRx has granted the underwriters a 30-day option to purchase up to an additional 555,000 shares of common stock at the initial public offering price to cover over-allotments, if any. The company's common stock began trading on the NASDAQ Capital Market on May 18, 2016 under the symbol "PZRX."
PZRX: 2.50 (-0.09)
PhaseRx Announces Pricing of Initial Public Offering
PR Newswire - Tue May 17, 8:18PM CDT
PhaseRx, Inc. (NASDAQZRX), a biotechnology company focused on developing mRNA therapeutics to treat orphan liver diseases, today announced the pricing of its initial public offering of 3,700,000 shares of common stock at an initial public offering price of $5.00 per share for an aggregate offering of $18.5 million, before underwriting discounts and commissions. In addition, PhaseRx has granted the underwriters a 30-day option to purchase up to an additional 555,000 shares of common stock at the initial public offering price to cover over-allotments, if any.
PZRX: 2.50 (-0.09)